Puma Biotechnology reported $-14787000 in Pre-Tax Profit for its fourth fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Acceleron Pharma XLRN:US $ -63.47M 6.06M
Agios Pharmaceuticals AGIO:US $ -82.79M 8.09M
Alexion Pharmaceuticals ALXN:US $ 940.1M 164.6M
Alnylam Pharmaceuticals ALNY:US $ -199.28M 44.32M
Amgen AMGN:US $ 2489M 145M
Bluebird Bio BLUE:US $ -205.74M 6.12M
Cerulean Pharma CERU:US $ -8.44M 0M
Clovis Oncology CLVS:US $ -66.41M 32.97M
Daiichi Sankyo 4568:JP Y 47062M 72506M
Esperion Therapeutics ESPR:US $ -90935000 13.54M
Mirati Therapeutics MRTX:US $ -135.68M 34.59M
Moderna Inc MRNA:US 1.26B 1.53B
Novartis NOVN:VX SF 3804M 295M
Ptc Therapeutics PTCT:US $ -117.88M 10.31M
Sangamo Biosciences SGMO:US $ -45.68M 5.11M
Sarepta Therapeutics SRPT:US $ -167.39M 21.09M
Spectrum Pharmaceuticals SPPI:US $ -49.98M 0M
Tg Therapeutics TGTX:US $ -90.63M 2.41M
Ultragenyx Pharmaceutical RARE:US $ -135.76M 111.82M
Vanda Pharmaceuticals VNDA:US $ 12.6M 2.18M